Skip to main content
SpringerLink
Log in

Semaglutide cost effective versus dulaglutide in Japan

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes

  2. proportion of glycosylated haemoglobin

  3. 2020 Japanese yen

Reference

  • Igarashi A, et al. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis Advances in Therapy : 1 Sep 2020. Available from: URL: https://doi.org/10.1007/s12325-020-01476-x

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Semaglutide cost effective versus dulaglutide in Japan. PharmacoEcon Outcomes News 862, 26 (2020). https://doi.org/10.1007/s40274-020-7144-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7144-3

Search

Navigation